1. Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1β, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators of inflammation. 2006;2006. Doi:10.1155/MI/2006/59206
2. Russell MA, Morgan N. The impact of anti-inflammatory cytokines on the pancreatic β-cell. Islets. 2014;6(3):e950547. Doi:10.4161/19382014.2014.950547
3. Blake R, Trounce IA. Mitochondrial dysfunction and complications associated with diabetes. Biochimica et Biophysica Acta (BBA)-General Subjects. 2014;1840(4):1404-12. Doi:10.1016/j.bbagen.2013.11.007
4. Sayin N, Kara N, Pekel G. Ocular complications of diabetes mellitus. World journal of diabetes. 2015;6(1):92. Doi:10.4239/wjd.v6.i1.92
5. Samadi N, Allahyari I, Zamanzadeh V, Dadkhah B, Mohammadi M. Educational Points for Prevention of Type 1 Diabetes and its Complications: A Systematic Review. J Clin Cell Immunol S. 2012;2:2.
6. Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin+ fenofibrate combination therapyand fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clinical therapeutics. 2004;26(10):1599-607.
7. Hansrani M, Stanford J, McIntyre G, Bottasso O, Stansby G. Immunotherapy for the prevention of myointimal hyperplasia after experimental balloon injury of the rat carotid artery. Angiology. 2010;61(5):437-42. Doi:10.1177/0003319710366128
8. Tarrés MC, Gayol MdC, Picena JC, Alet N, Bottasso O, McIntyre G, et al. Beneficial effects of immunotherapy with extracts derived from Actinomycetales on rats with spontaneous obesity and diabetes. Immunotherapy. 2012;4(5):487-97. Doi:10.2217/imt.12.37
9. Khordadmehr M, Ghaderi S, Mesgari-Abbasi M, Jigari-Asl F, Nofouzi K, Tayefi-Nasrabadi H, et al. The Beneficial Effects of Actinomycetales Immune Modulators in the Pancreas of Diabetic Rats. Advanced Pharmaceutical Bulletin. 2021;11(2):371. Doi:10.34172/apb.2021.035
10. Khordadmehr M, Ghaderi S, Abbasi MM, Nofouzi K, McIntyre G. The improvement effects of Gordonia bronchialis on male fertility of rats with diabetes mellitus induced by streptozotocin. Pharmaceutical Sciences. 2019;25(3):227-34.
11. Mesgari-Abbasi M, Ghaderi S, Khordadmehr M, Nofouzi K, Tayefi-Nasrabadi H, McIntyre G. Enteroprotective effect of Tsukamurella inchonensis on streptozotocin induced type 1 diabetic rats. Turkish Journal of Biochemistry. 2019;44(5):683-91.
12. Hassanalilou T, Payahoo L, Shahabi P, Abbasi MM, Jafar-abadi MA, Bishak YK, et al. The protective effects of Morus nigra L. leaves on the kidney function tests and histological structures in streptozotocin-induced diabetic rats. Biomed Res. 2017;28(14):6113-8.
13. Zafar M, Naqvi SN-u-H, Ahmed M, Kaimkhani ZA. Altered Liver Morphology and Enzymes in Streptozotocin Induced Diabetic Rats. International journal of morphology. 2009;27(3).
14. Arkkila PE, Koskinen PJ, Kantola IM, Rönnemaa T, Seppänen E, Viikari JS. Diabetic complications are associated with liver enzyme activities in people with type 1 diabetes. Diabetes Research and Clinical Practice. 2001;52(2):113-8. Doi:10.1016/s0168-8227(00)00241-2
15. Edet E, Atangwho I, Akpanabiatu M, Edet T, Uboh F, David-Oku E. Effect of Gongronema latifolium leaf extract on some liver enzymes and protein levels in diabetic and non diabetic rats. J Pharm Biomed Sci. 2011;1(5):104-7.
16. Özer G, Teker Ζ, Cetiner S, Yılmaz M, Topaloglu AK, Önenli-Mungan N, et al. Serum IL-1, IL-2, TNFα and INFγ levels of patients with type 1 diabetes mellitus and their siblings. Journal of Pediatric Endocrinology and Metabolism. 2003;16(2):203-10.
17. Tomoda T, Kurashige T, Taniguchi T. Imbalance of the interleukin 2 system in children with IDDM. Diabetologia. 1994;37:476-82. Doi:10.1007/s001250050135
18. Wagner R, Bonifacio E, Bingley P, Genovese S, Reinwein D, Bottazzo G. Low interleukin-2 receptor levels in serum of patients with insulin-dependent diabetes. The clinical investigator. 1994;72:494-8. Doi:10.1007/BF00207476
19. Karlsson Faresjö M, Ernerudh J, Ludvigsson J. Cytokine profile in children during the first 3 months after the diagnosis of type 1 diabetes. Scandinavian journal of immunology. 2004;59(5):517-26. Doi:10.1111/j.0300-9475.2004.01420.x
20. Abbas MA, Abraham D, Kushner JP, McClain DA. Anti‐obesity and pro‐diabetic effects of hemochromatosis. Obesity. 2014;22(10):2120-2. Doi:10.1002/oby.20839
21. Davì G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation. 2003;107(25):3199-203. Doi:10.1161/01.CIR.0000074205.17807.D0
22. Erbağci AB, Tarakçioğlu M, Coşkun Y, Sivasli E, Namiduru ES. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clinical biochemistry. 2001;34(8):645-50. Doi:10.1016/s0009-9120(01)00275-2
23. Khattab MH, Shahwan MJ, Hassan NAGM, Jairoun AA. Abnormal High-sensitivity C-reactive Protein is Associated with an Increased Risk of Cardiovascular Disease and Renal Dysfunction among Patients Diagnosed with Type 2 Diabetes Mellitus in Palestine. Review of Diabetic Studies. 2022;18(1):27-33.
24. Tietz NW. Clinical guide to laboratory tests. Clinical guide to laboratory tests1995. p. 1096-.
25. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman J, Smith JA, et al. Short protocols in molecular biology. New York. 1992;275:28764-73.
26. Klopfleisch R. Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology-a systematic review. BMC veterinary research. 2013;9:1-15. Doi:10.1186/1746-6148-9-123
